Autologous chondrocytes - ProChon Biotech

Drug Profile

Autologous chondrocytes - ProChon Biotech

Alternative Names: BioCart; BioCartII

Latest Information Update: 13 Aug 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ProChon Biotech
  • Developer Histogenics Corporation; ProChon Biotech
  • Class Cell therapies
  • Mechanism of Action Cartilage replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Knee injuries

Most Recent Events

  • 16 May 2011 ProChon Biotech has been acquired by Histogenics Corporation
  • 30 Jan 2001 Launched for Knee injuries in Israel (Implant)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top